Renovaro Biosciences Statistics
Total Valuation
RENB has a market cap or net worth of $219.78 million. The enterprise value is $228.04 million.
| Market Cap | 219.78M |
| Enterprise Value | 228.04M |
Important Dates
The last earnings date was Wednesday, May 15, 2024, after market close.
| Earnings Date | May 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RENB has 147.50 million shares outstanding. The number of shares has increased by 92.02% in one year.
| Shares Outstanding | 147.50M |
| Shares Change (YoY) | +92.02% |
| Shares Change (QoQ) | +63.21% |
| Owned by Insiders (%) | 25.55% |
| Owned by Institutions (%) | 4.92% |
| Float | 105.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.30 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06, with a Debt / Equity ratio of 0.05.
| Current Ratio | 0.06 |
| Quick Ratio | n/a |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.26 |
Financial Efficiency
Return on equity (ROE) is -70.60% and return on invested capital (ROIC) is -30.07%.
| Return on Equity (ROE) | -70.60% |
| Return on Assets (ROA) | -55.90% |
| Return on Capital (ROIC) | -30.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.49M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +65.83% in the last 52 weeks. The beta is 0.44, so RENB's price volatility has been lower than the market average.
| Beta (1Y) | 0.44 |
| 52-Week Price Change | +65.83% |
| 50-Day Moving Average | 1.93 |
| 200-Day Moving Average | 2.98 |
| Relative Strength Index (RSI) | 51.22 |
| Average Volume (30 Days) | 439,714 |
Short Selling Information
The latest short interest is 1.93 million, so 1.31% of the outstanding shares have been sold short.
| Short Interest | 1.93M |
| Short Previous Month | 2.13M |
| Short % of Shares Out | 1.31% |
| Short % of Float | 1.82% |
| Short Ratio (days to cover) | 5.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -53.28M |
| Pretax Income | -53.93M |
| Net Income | -53.93M |
| EBITDA | -52.90M |
| EBIT | -53.02M |
| Earnings Per Share (EPS) | -$0.78 |
Balance Sheet
The company has $312,697 in cash and $8.57 million in debt, giving a net cash position of -$8.26 million or -$0.06 per share.
| Cash & Cash Equivalents | 312,697 |
| Total Debt | 8.57M |
| Net Cash | -8.26M |
| Net Cash Per Share | -$0.06 |
| Equity / Book Value | 168.60M |
| Book Value Per Share | 1.14 |
| Working Capital | -19.65M |
Cash Flow
In the last 12 months, operating cash flow was -$10.82 million and capital expenditures -$53,019, giving a free cash flow of -$10.87 million.
| Operating Cash Flow | -10.82M |
| Capital Expenditures | -53,019 |
| Free Cash Flow | -10.87M |
| FCF Per Share | -$0.10 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RENB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -92.02% |
| Shareholder Yield | -92.02% |
| Earnings Yield | -24.54% |
| FCF Yield | -4.95% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |